Detalhe da pesquisa
1.
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Blood
; 143(17): 1702-1712, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211337
2.
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Blood
; 143(7): 582-591, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971194
3.
Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
J Natl Compr Canc Netw
; 22(4)2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754469
4.
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 201(5): 897-904, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626914
5.
Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
Oncologist
; 28(4): 309-318, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36723874
6.
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Blood
; 138(17): 1535-1539, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289017
7.
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Am J Hematol
; 98(2): 338-347, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36415104
8.
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Blood
; 135(18): 1541-1547, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978210
9.
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Haematologica
; 107(5): 1163-1171, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162182
10.
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.
Br J Haematol
; 194(4): 730-733, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713429
11.
How to Sequence Therapies in Waldenström Macroglobulinemia.
Curr Treat Options Oncol
; 22(10): 92, 2021 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426943
12.
Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents.
J Natl Compr Canc Netw
; 18(4): 420-427, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259788
13.
Long-term outcome of kidney transplantation in AL amyloidosis.
Kidney Int
; 95(2): 405-411, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30580886
14.
Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Biol Blood Marrow Transplant
; 25(5): e169-e173, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30639823
15.
Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis.
Am J Hematol
; 94(10): 1098-1103, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292986
16.
High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Biol Blood Marrow Transplant
; 24(1): 127-132, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865972
17.
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Biol Blood Marrow Transplant
; 24(9): 1823-1827, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29933072
18.
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Blood
; 137(21): 2987-2989, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728443
19.
Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients.
Transfus Apher Sci
; 57(3): 411-415, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29731423
20.
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Br J Haematol
; 195(3): 466-468, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355802